Salvage therapy with azacitidine increases regulatory T cells in peripheral blood of patients with AML or MDS and early relapse after allogeneic blood stem cell transplantation

Leukemia

Volumn 27, Issue 9, 2013, Pages 1910-1913

  Schroeder, T ^a   Frobel J ^a   Cadeddu, R P ^a   Czibere, A ^a   Dienst, A ^a   Platzbecker, U ^b   Bug, G ^c   Uharek, L ^d   Fenk, R ^a   Germing, U ^a   Kroger N ^e   Haas, R ^a   Kobbe, G ^a  

^a HEINRICH HEINE UNIVERSITY   (Germany)

^b UNIVERSITY HOSPITAL CARL GUSTAV CARUS   (Germany)

^c GOETHE UNIVERSITY   (Germany)

^d CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^e UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

AZACITIDINE; TRANSCRIPTION FACTOR FOXP3;

ACUTE GRANULOCYTIC LEUKEMIA; ALLOGENEIC STEM CELL TRANSPLANTATION; CD3+ T LYMPHOCYTE; CD4+ T LYMPHOCYTE; GRAFT VERSUS HOST REACTION; HELPER CELL; HUMAN; LETTER; LEUKEMIA RELAPSE; LEUKEMIA REMISSION; LYMPHOCYTE SUBPOPULATION; MAINTENANCE THERAPY; MULTIPLE CYCLE TREATMENT; MYELODYSPLASTIC SYNDROME; PATIENT MONITORING; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; SALVAGE THERAPY;

ANTIMETABOLITES, ANTINEOPLASTIC; AZACITIDINE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; LEUKEMIA, MYELOID, ACUTE; LYMPHOCYTE COUNT; MYELODYSPLASTIC SYNDROMES; RECURRENCE; SALVAGE THERAPY; T-LYMPHOCYTES, REGULATORY; TRANSPLANTATION, HOMOLOGOUS;

EID: 84883741973     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2013.64     Document Type: Letter

References (12)

1. Pavletic SZ, Kumar S, Mohty M, de Lima M, Foran JM, Pasquini M et al. NCI First International Workshop on the Biology, Prevention, and Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation: Report from the Committee on the Epidemiology and Natural History of Relapse following Allogeneic Cell Transplantation. Biol Blood Marrow Transplant J Am Soc Blood Marrow Transplant 2010; 16: 871-890.
2. Roddie C, Peggs KS. Donor lymphocyte infusion following allogeneic hematopoietic stem cell transplantation. Expert Opin Biol Ther 2011; 11: 473-487.
3. Czibere A, Bruns I, Kroger N, Platzbecker U, Lind J, Zohren F et al. 5-Azacytidine for the treatment of patients with acute myeloid leukemia or myelodysplastic syndrome who relapse after allo-SCT: a retrospective analysis. Bone Marrow Transplant 2010; 45: 872-876.
4. Graef T, Kuendgen A, Fenk R, Zohren F, Haas R, Kobbe G. Successful treatment of relapsed AML after allogeneic stem cell transplantation with azacitidine. Leuk Res 2007; 31: 257-259. (Pubitemid 44854182)
5. Schroeder T, Czibere A, Platzbecker U, Bug G, Uharek L, Luft T et al. Azacitidine and donor lymphocyte infusions as first salvage therapy for relapse of AML or MDS after allogeneic stem cell transplantation. Leukemia 2013; 27: 1229-1235.
6. Lubbert M, Bertz H, Wasch R, Marks R, Ruter B, Claus R et al. Efficacy of a 3-day, low-dose treatment with 5-azacytidine followed by donor lymphocyte infusions in older patients with acute myeloid leukemia or chronic myelomonocytic leukemia relapsed after allografting. Bone Marrow Transplant 2010; 45: 627-632.
7. Schmid C, Labopin M, Nagler A, Bornhauser M, Finke J, Fassas A et al. Donor lymphocyte infusion in the treatment of first hematological relapse after allogeneic stem-cell transplantation in adults with acute myeloid leukemia: a retrospective risk factors analysis and comparison with other strategies by the EBMT Acute Leukemia Working Party. J Clin Oncol 2007; 25: 4938-4945. (Pubitemid 350225492)
8. Choi J, Ritchey J, Prior JL, Holt M, Shannon WD, Deych E et al. In vivo administration of hypomethylating agents mitigate graft-versus-host disease without sacrificing graft-versus-leukemia. Blood 2010; 116: 129-139.
9. Edinger M, Hoffmann P, Ermann J, Drago K, Fathman CG, Strober S et al. CD4\+ CD25\+ regulatory T cells preserve graft-versus-tumor activity while inhibiting graftversus-host disease after bone marrow transplantation. Nat Med 2003; 9: 1144-1150. (Pubitemid 37173698)
10. Sanchez-Abarca LI, Gutierrez-Cosio S, Santamaria C, Caballero-Velazquez T, Blanco B, Herrero-Sanchez C et al. Immunomodulatory effect of 5-azacytidine (5-azaC): potential role in the transplantation setting. Blood 2010; 115: 107-121.
11. Goodyear OC, Dennis M, Jilani NY, Loke J, Siddique S, Ryan G et al. Azacitidine augments expansion of regulatory T cells after allogeneic stem cell transplantation in patients with acute myeloid leukemia. Blood 2012; 119: 3361-3369.
12. Costantini B, Kordasti S, Kulasekararaj AG, Jiang J, Seidl T, Perez Abellan P et al. The effects of 5-azacytidine on the function and number of regulatory T-cells and T-effectors in myelodysplastic syndrome. Haematologica 2012; 98: 1196-1205.